CTLA-4 overexpression in CD19 þ /CD5 þ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients
TO THE EDITOR
The gradual accumulation of malignant cells in B-CLL is probably due to disturbances in the balance between programmed cell death and cell proliferation. It has been recently suggested that inhibitory CTLA-4 (cytotoxic T lymphocyteassociated antigen 4; CD152) molecule may be involved in the cell cycle machinery; 1,2 however, the role of CTLA-4 in cell cycle progression is relatively well understood in T cells only. CTLA-4 seems to prolong the progression through the G1 phase of the cell cycle by upregulation of cyclin D2 and inhibition of cyclin D3, cdk4, and cdk6 production.
1,2 CTLA-4 also affects the degradation of cyclin-dependent kinase inhibitor p27 KIP1 and contributes to its earlier and stronger re-expression during the late stages of T-cell activation. 1, 2 As little is known about CTLA-4 expression/function in normal and neoplastic B cells, we have extended our previous study concerning G1 cell cycle phase regulators in B-CLL cells 3 in the context of their association with the expression of CTLA-4.
We estimated both the surface and intracellular expression of CTLA-4 molecule in peripheral blood CD19 þ /CD5 þ lymphocytes derived from B-CLL patients in relation to the stage of the disease and the cell cycle phase distribution of these lymphocytes. We also investigated the associations between CTLA-4 expression and the levels of cyclin D2, cyclin D3, and p27 KIP1 in these cells. Based on the fact that CTLA-4 gene polymorphisms were reported to affect CTLA-4 protein level, 4 the relationships between the levels of CTLA-4 expression in leukemic cells and CTLA-4 gene polymorphisms in B-CLL patients were also examined.
A total of 39 B-CLL patients (in stages 0-IV according to the Rai classification) and 21 age-and sex-matched healthy controls entered the study. The criteria for diagnosis and disease progression have been previously described. 5 Direct surface and intracellular immunofluorescence staining were performed for the evaluation of the expressions of all studied proteins and the distribution of cell cycle phases. Cells were then analyzed by flow cytometry using a FACScalibur. Data were processed by CellQuest Software. Total genomic DNA was isolated from whole frozen blood. Both SNPs (A49G, C-318T) were identified using ABI PRISM SNaPshot ddNTP Primer Extension Reaction Kit and detected using the ABI PRISM s 310 capillary electrophoresis system. The STR polymorphism at locus 642 was studied by PCR and a fluorescence-based technique using a fluorescently labeled primer and GENESCANt-350ROXt STANDARD as an internal lane standard for an ABI PRISM s 310 capillary electrophoresis system. To compare independent variables, the Mann-Whitney U test was used. Spearman's rank measured the correlation between marker expression, Rai stages or cell cycle phase distribution. Statistical calculations were performed using the Statistica 5.1 program.
The present study showed for the first time a significantly higher mean proportion of CD19 þ /CD5 þ cells expressing CTLA-4 molecule both on the cell surface (sCTLA-4) and intracellularly (cCTLA-4) in all B-CLL patients compared with the control group (P ¼ 0.001 and Po0.000001) ( Table 1 ). In B-CLL patients, both sCTLA-4 and cCTLA-4 expression relative to the single cell, as measured semiquantitatively by estimating the mean fluorescence intensity of CTLA-4 (MFI), was also markedly elevated within the subset of CD19 þ /CD5 þ cells compared with the normal population (P ¼ 0.009 and P ¼ 0.000005, respectively) ( Table 1) . Furthermore, we found positive correlation between sCTLA-4 as well as cCTLA-4 expression in leukemic cells and Rai stage (r s ¼ 0.62; P ¼ 0.003 and r s ¼ 0.43; P ¼ 0.05, respectively) ( Figure 1a and b).
To explain the great variation in CTLA-4 expression in leukemic cells, the B-CLL patients were stratified by genotype at the promoter (designated as ). Furthermore, based on the number of (AT) repeats starting from position 642 in exon 4, we subdivided the patients into three groups with respect to the presence or absence of the 82 base-pair (bp) allele. The genotype distribution among B-CLL patients is shown in Table 2 . The patients categorized into groups according to these genotypes were then compared with regard to CTLA-4 expression. As for CTLA-4 gene dimorphisms at the promoter or exon 1, the differences in CTLA-4 expression, evaluated either as a proportion of triple-positive cells or MFI values, between genotype-related groups of patients were not statistically significant (Table 2) . However, we observed that the intracellular distribution of CTLA-4 was markedly higher in B-CLL patients carrying allele with 82 (AT) repeats than the longer allele of 82 bp in exon 4 In addition to increased CTLA-4 expression in B-CLL cells, we also found positive associations between the proportions of leukemic cells coexpressing sCTLA-4 as well as those expressing cCTLA-4 and the level of cyclin D2 (r s ¼ 0.42; P ¼ 0.01 and r s ¼ 0.43; P ¼ 0.02, respectively) (Figure 2a and b) . In contrast, sCTLA-4 and cCTLA-4 expression inversely correlated with the The positive correlations between disease progression (Rai stages) and the percentage of CD19 þ /CD5 þ cells coexpressing CTLA-4 on the surface (a) and intracellularly (b). proportion of CD19 þ /CD5 þ /cyclin D3 þ lymphocytes (r s ¼ À0.4; P ¼ 0.03 and r s ¼ À0.41; P ¼ 0.04, respectively) (Figure 2c and d) . None of the associations concerning CTLA-4 and cyclin expression existed in healthy subjects. Moreover, a positive correlation between the percentage of leukemic cells coexpressing cCTLA-4 and the proportion of these lymphocytes expressing p27
KIP1 protein was also shown (r s ¼ 0.41; P ¼ 0.04) (Figure 2e) . The same association existed in the control group (r s ¼ 0.45; P ¼ 0.05). In B-CLL patients, the proliferative activity, calculated by the DNA content of CD19 þ cells, was very low, as was postulated previously, 3 and the cell cycle phase distribution in these cells did not differ significantly from those we observed in normal B lymphocytes. However, in the present study, a positive correlation has been found between the number of cells in the G0/G1 phase of the cell cycle and the percentage of CD19 þ /CD5 þ cells coexpressing sCTLA-4 molecule in the group of patients only (r s ¼ 0.41; P ¼ 0.05) (Figure 2f) .
To the best of our knowledge, this is the first report on the significantly increased surface and cytoplasmic expression of CTLA-4 in leukemic CLL-B cells compared with a normal population of CD19 þ /CD5 þ cells. Although the presence of CTLA-4 epitopes in CD45 þ /CD19 þ /CD7 þ cells was recently described on either the surface or the cytoplasm in three out of four and four out of four patients, respectively, 6 our present study is the first one made in a large group of B-CLL patients. It is also noteworthy that the mean level of CTLA-4 expression in B-CLL cells was correlated with disease progression. The great variations in CTLA-4 expression observed in leukemic cells seem to be related, at least in part, to CTLA-4 gene polymorphisms, which is also a novel finding. In particular, our observation that in B-CLL patients the shortest (AT)n allele, 82 bp, gave rise to increased levels of cytoplasmic CTLA-4 compared with the longer alleles is consistent with the finding that the length of the (AT)n repeat affects the stability of the CTLA-4 mRNA. 7 The mechanisms of the increased CTLA-4 expression in leukemic cells are not yet fully understood. Based on the fact that CTLA-4 is inducible during T-and B-cell activation, and neoplastic cells from T-cell chronic lymphocytic leukemia (T-CLL), which present a T-resting-like phenotype, were completely negative for CTLA-4 epitopes, 6 we suggest that the strongly elevated CTLA-4 expression in B-CLL cells is consistent with the observation that these resting cells are partially activated rather than quiescent. 3 Furthermore, the positive correlation between the percentage of CD19 þ /CD5 þ cells positive for CTLA-4 and those with the presence of cyclin D2, induced by growth factors in early G1 phase, strengthens the above suggestion and points to the possibility that one of the mechanisms regulating G1 phase progression by CTLA-4 is the maintenance of a high level of cyclin D2 expression in leukemic cells. However, in spite of the higher proportions of leukemic cells coexpressing cyclin D2, these cells did not exit G1 phase, since a very low subset of them were in S phase. The reason for this phenomenon is probably related to the fact that CTLA-4 engagement during suboptimal activation of lymphocytes inhibits cyclin D3 induction in late G1 phase. 1 The negative correlation between the mean percentages of CD19 þ /CD5 þ /cyclin D3 þ and CD19 þ /CD5 þ /CTLA-4 þ lymphocytes in B-CLL patients studied seems to be consistent with this observation. In fact, CTLA-4 in naïve T cells prolongs early G1 phase and prevents rapid progression to late G1. 2 It is of special interest to explain also whether the markedly higher level of p27 KIP1 protein in B-CLL cells confirmed in this study might be sustained by CTLA-4-dependent protection of p27 KIP1 from degradation, as was suggested previously in normal T cells. 1 Our finding of a positive correlation between the elevated expression levels of CTLA-4 and p27 KIP1 in neoplastic CD19 þ /CD5 þ cells appears to support this concept.
In light of previous studies showing the suppressory role of CTLA-4 in G1 phase progression in T cells, 1,2 our observation concerning its association with cell cycle regulators favors the interpretation that CTLA-4 might contribute to an arrest of leukemic cells in this cell cycle phase. Furthermore, our notion of a positive correlation between the mean percentage of leukemic CD19 þ /CD5 þ cells coexpressing CTLA-4 and the mean proportion of CD19 þ lymphocytes in G0/G1 phase seems to strengthen this idea. Additional experiments are required to ascertain if the observed correlations of CTLA-4 with p27
KIP1 and D-type cyclins are truly functional and CTLA-4 may thereby act as a possible regulator of G1 phase progression in B-CLL cells. Whether it plays a casual role in B-CLL pathogenesis or represents only a secondary change also remains to be elucidated.
